Michael S. Rosol
2018
In 2018, Michael S. Rosol earned a total compensation of $11.5K as Chief Medical Officer at Navidea Biopharmaceuticals.
Compensation breakdown
Non-Equity Incentive Plan | $2,949 |
---|---|
Salary | $8,542 |
Total | $11,491 |
Rosol received $8.5K in salary, accounting for 74% of the total pay in 2018.
Rosol also received $2.9K in non-equity incentive plan.
Rankings
In 2018, Michael S. Rosol's compensation ranked 14,214th out of 14,244 executives tracked by ExecPay.
Classification | Ranking | Percentile |
---|---|---|
All | 14,214 | 0th |
Manufacturing | 5,759 | 0th |
Chemicals And Allied Products | 2,127 | 0th |
Drugs | 1,816 | 0th |
In Vitro and In Vivo Diagnostic Substances | 72 | 0th |
Rosol's colleagues
We found four more compensation records of executives who worked with Michael S. Rosol at Navidea Biopharmaceuticals in 2018.
News
Navidea Biopharmaceuticals Chief Medical Officer Michael Rosol's 2022 pay slips 8% to $430K
October 5, 2023
Navidea Biopharmaceuticals CEO Jed Latkin's 2021 pay rises 10% to $1.3M
October 24, 2022
Navidea Biopharmaceuticals CEO Jed Latkin's 2020 pay jumps 66% to $1.2M
August 2, 2021
Navidea Biopharmaceuticals CEO Jed Latkin's 2019 pay rises 16% to $740K
July 31, 2020
Navidea Biopharmaceuticals CEO Michael Goldberg's 2018 pay jumps 76% to $1.5M
June 28, 2019